Is ASND a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on YORVIPATH is carrying the model, with revenue (ttm) at ~EUR 866 million (about ~$1.0 billion), up ~135% year over year. The bear case rests on revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. Analysts covering it are spread from $261.24 to $358.98, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $261.24, +2.3% from the $255.41 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

YORVIPATH is carrying the model. Hypoparathyroidism had no chronic hormone-replacement standard for years after Takeda withdrew Natpara, leaving a diagnosed population managed on calcium and active vitamin D. The most optimistic analyst target on ASND is $358.98, +40.6% from the $255.41 price. That figure is only reachable if this thesis works close to its best case.

Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. AstraZeneca's eneboparatide and other parathyroid hormone programs target the same indication, while BioMarin's Voxzogo is entrenched in achondroplasia and a long-acting successor is in development, and oral FGFR3 approaches from companies including Tyra Biosciences could reframe the category entirely. YUVIWEL was cleared under accelerated approval, which carries confirmatory evidence obligations that can constrain or withdraw a label. Ascendis is a foreign private issuer that reports in euros and files Form 20-F, so currency translation and a lighter interim disclosure cadence than a domestic filer both apply. On the legal side, Ascendis is an appellant in patent litigation against BioMarin at the Federal Circuit (No. 26-1026), and plaintiffs' firms publicized securities class action investigation notices in 2023 following the FDA deficiency letter on TransCon PTH, though those solicitations are not the same as a filed complaint and no active securities-fraud class action was identified as of August 2026. The most pessimistic published target is $261.24, +2.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Ascendis Pharma is a Danish biopharmaceutical company whose TransCon prodrug platform powers three approved rare-disease medicines: SKYTROFA, YORVIPATH and YUVIWEL.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (YORVIPATH is carrying the model) stalling in the reported numbers rather than in the narrative, the risk above (revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

ASND is the Nasdaq ticker for Ascendis Pharma A/S, a biopharmaceutical company headquartered in Hellerup, Denmark. US investors hold American Depositary Shares rather than the Danish ordinary shares directly. The company uses its TransCon prodrug technology to develop long-acting versions of established therapies for rare endocrine and growth conditions.

Three approved products generate revenue. SKYTROFA (lonapegsomatropin) treats pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) treats adult hypoparathyroidism, and YUVIWEL (navepegritide) received accelerated FDA approval in May 2026 for pediatric achondroplasia. YORVIPATH is by far the largest contributor at roughly ~EUR 197 million in the first quarter of 2026.

It depends on which line you read. Trailing reported net income of roughly ~EUR 496 million is dominated by a one-time deferred tax asset recognition of roughly ~EUR 679 million. Trailing operating income is slightly negative, at roughly negative ~1.7 percent margin, and the company pointed to non-IFRS net profit of roughly ~EUR 18 million in the first quarter of 2026 as the underlying figure.